Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 6, 2007

Idera Extends Asthma and Allergy Collaboration with Novartis

  • Novartis extended the the research phase of its collaboration with Idera Pharmaceuticals, which begain in June, 2005, by one year.

    Idera will receive a $1 million upfront, and Novartis will continue to fund research.

    Idera’s agreements with Novartis are structured in two phases. During the research phase, Idera and Novartis are working to evaluate TLR9 agonists. Novartis may select candidates for further development through human clinical proof-of-concept trials. It may then elect to implement the next phase to complete the development and commercialize one or more of the TLR9 agonist candidates in the fields of asthma and allergy.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »